comparemela.com
Home
Live Updates
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis : comparemela.com
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody...
Related Keywords
Jersey ,
David Lee ,
Johnson ,
None Of Cilag Holding ,
Janssen Research Development ,
Janssen Biotech Inc ,
Cilag Holding ,
Numab Therapeutics ,
Global Immunology Therapeutic Area Head ,
Johnson Innovative ,
Candice Long ,
Worldwide Vice President ,
Hart Scott Rodino Antitrust Improvements Act ,
Innovative Medicine ,
Janssen Research ,
Janssen Biotech ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Yellow Jersey Therapeutics ,
Kaken Pharmaceutical ,
Asia Pacific ,
comparemela.com © 2020. All Rights Reserved.